Collgard Biopharmaceuticals, Ltd is a clinical stage private company with multiple Phase II development programs underway for Tempostatin(TM), a first-in-class small-molecule therapeutic. Tempostatin(TM) inhibits two key cellular processes common to both cancer and fibrosis.

  • In cancer, Tempostatin(TM) inhibits the proliferation, invasion and spread of cancer cells;
  • In fibrosis, Tempostatin(TM) inhibits the formation of scar tissue and promotes normal tissue repair.

    Tempostatin(TM)'s selective, dual-mode-of-action inhibits stromal activation / recruitment and prevents progressive changes in extracellular matrix protein. As such, it addresses substantial unmet needs in billion-dollar worldwide markets for:
  • Cancer (including bladder, brain, soft tissue, skin, others)
  • Organ fibrosis (including liver, kidney, heart, others)
  • Coronary restenosis (after stenting, angioplasty)
  • Dermal fibrosis (scleroderma, scar formation)

    Collgard holds strong intellectual property to protect all clinical applications of Tempostatin(TM).

    The company maintains offices in Israel and in the U.S.

    CEO is Dr. Bruce Bach.

    • D-PHARM is a biopharmaceutical company focused on the clinical development of innovative lipid-based drugs for the treatment of central nervous system disorders, cancer and autoimmune diseases.

    D-Pharm generates a rich pipeline of safe and effective pre-clinical and clinical products from its three proprietary technology engines. D-Pharm's pipeline includes two products in Phase II for epilepsy and acute stroke, and four in pre-clinical development for Parkinson's disease, Alzheimer's disease, psoriasis and neuropathic pain.

    D-Pharm has a growing patent portfolio including patents and pending applications covering its innovative technologies and products.

    D-Pharm's headquarters, research labs and GMP pilot plant for scale-up and process development are based in Israel, with a Business Development unit in the USA. The company employs 30 people with expertise in medicinal and scale-up chemistry, lipid biochemistry, cell biology, pharmacology, product development and analytics for polar lipids and lipophilic chelators.

    CEO is Dr. Alex Kozak.

    E&C Medical Intelligence is dedicated to improving the quality of obstetrical care while easing the job of the obstetrics professional. E&C's team consists of more than 30 medical and obstetrical professionals with E&C's impressive group of software engineers, customer support specialists and IT professionals.

    The leading product IPROB (Intelligent Patient Record for Obstetrics) is the most advanced documentation and case management support software ever created for the Obstetrics environment. In fact, it is the only product on the market that offers real-time clinical practice support along with comprehensive documentation for OB practitioners.

    To-date, the customizable software system has logged more than 15,000 births and is installed and operates in several leading obstetrical departments in the United States. Today, E&C is recognized as a pioneer in the development of automated case management support and documentation for the obstetrics environment and serves the obstetrical community with powerful, practice-specific tools for the prenatal, L&D and postpartum care continuum.

    E&C holds headquarters in New York, U.S., and R&D facilities in Jerusalem, Israel.

    CEO is Dr. Eyal Ephrat.

    Gamida Cell, Ltd. is an early stage company engaged in the dynamic field of cell therapy. Using a proprietary platform technology for the ex-vivo modulation of cell proliferation and differentiation, the company is developing a kit for the expansion of stem cells derived from umbilical cord blood as a first product. This kit will provide a crucial and revolutionary tool for stem cell transplantation in patients with leukemia or lymphoma. Clinical trials are expected to start in 2001. The company is collaborating with luminary cord blood banks and transplantation centers in Europe and the US. Gamida Cell is developing relationships with strategic partners to develop additional applications in non-hemopoietic stem cells and in gene therapy. The company has applied for broad worldwide patent protection of its core technology. Gamida Cell is based in Jerusalem, Israel.

    TransScan develops innovative solutions for the non-invasive, accurate and cost-effective detection of breast cancer, based on a powerful and patented technology called TransSpectral Impedance Scanning. The device, T-Scan 2000 underwent clinical trials in the United States, Europe and Israel and received FDA approval as an adjunct to mammography. A modified version of TS 2000 (T-Scan 2000ED) is currently under investigation for the detection of breast cancer in women below the age recommended age for screening mammography. The unique benefit of T-Scan is that the procedure is quick, efficient, painless and does not expose the breast to radiation. T-Scan uses low-level electric currents that are measured to produce real-time images of the electrical impedance properties of the breast or other tissue. Cytological and histological differences in malignant, involving changes in cell membrane structure and cellular water and electrolyte content, result in a significant change in tissue electrical impedance. The impedance properties of the breast can be measured and evaluated by an algorithm to estimate the likelihood that a carcinoma is present. In addition to breast cancer detection, the T-Scan technology platform can be applied to other clinical applications and a number of exciting clinical uses are under investigation. TransScan is headed by Mr. Noam Karstaedt of Denali Ventures.

    HyperRoll Incorporated provides software that enables business intelligence (BI) solutions to become massively scalable : delivering previously unattainable levels of speed, data volume and business dimensions. Companies like ConAgra Foods, GE, and Nortel have already experienced HyperRoll's benefits. Our patented software improves the performance of business intelligence solutions by an unprecedented 100 times. As a result, you can support more users and higher data volumes while dramatically reducing query response times.

    HyperRoll's software is based on advanced algorithms. Our unique architecture complements your existing BI solution, without requiring any new hardware or other resources. Our software installs on the same system you have in place for your data mart or data warehouse : only now its performance will increase by 100 times. You will see substantial improvement in data aggregation time and ad hoc query response time : additionally, your system's CPU and disk requirements will be reduced. After switching HyperRoll, our customers find they can spend more of their time developing and deploying new business solutions instead of wasting time trying to maintain an old, bloated, data warehouse.

    HyperRoll holds headquarters in Mountain View, CA and a development center in Israel.

    CEO is Mr. Michael Bealmear.

    Real-Time Radiography (RTR) is developing the next generation direct Digital Radiography (DR) detectors based on its proprietary mercuric iodide x-ray photoconductor technology. The company manufactures unique detectors that are capable of operating in both dynamic (fluoroscopic) and static imaging applications. The detector's exceptional sensitivity to x-rays, significant cost advantages, and low voltage operation make it unsurpassed in providing high image quality at low doses of radiation and at a reduced expense to the end user.

    RTR was founded in 1998, based on technology licensed from The Hebrew University in Jerusalem.

    CEO is Mr. Shaul Dukeman.

    Applied Spectral Imaging (ASI) has developed a light-related platform imaging technology called SpectraCube. Patented worldwide, SpectraCube uses light's unique qualities to display information in an image that cannot be detected with existing imaging technologies. Similar to the wide impact of the X-Ray and ultrasound, SpectraCube has the potential to be a crucial imaging technology of the future. ASI has challenged itself with the strategic mission to increase shareholder value by developing and commercializing state-of-the-art imaging systems that satisfy customer needs and that make significant and sustainable contributions to their fields of use. In ophthalmology, ASI has developed the OASIS? system, which creates color-coded oxygen saturation maps to display the oxygen saturation levels in the retinal blood vessels. This approach has the potential to identify the onset of retinal disease much earlier than present techniques. In cytogenetics, ASI developed the award-winning SKY system which has revolutionized the diagnosis of cancer and pre-natal testing by making the results clearer and easier to interpret. An upcoming product release for the pathology market promises to do the same in that crucial field as well.Throughout the year 2000 ASI continued to develop its strategic relationship with Welch Allyn, a recognized world leader in the field of Opthomology. Aside from an earlier $5.5 Million strategic investment from Welch Allyn, ASI also closed an $11 Million financing round in August.

     



    about_us about_us1 about_us2 contact contact1 contact2 for_the index portfolio thanks